Immunitybio Inc

IBRX · NASDAQ · Healthcare / Biotechnology

$8.14-0.23 (-2.75%)

Close Sep 15, 2026 · end-of-day

Market Stats

Previous Close$8.37

Open$8.32

Day Range$7.85 – $8.34

52-Week Range$1.95 – $12.43

Volume8.91M

Market Cap$9.16B

P/E (TTM)0.00

Forward P/E123.46

EPS$-0.95

Dividend Yield0.00%

Beta0.14

50-Day Avg$7.81

200-Day Avg$7

Price History

Open in new tab

Loading price history…

About

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Company Details

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Richard Gerald Adcock
Employees: 684
Headquarters: 3530 John Hopkins Court, San Diego, CA, United States, 92121, USA
Website: https://immunitybio.com

Leadership

Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc.Founder, Executive Chairman and Global Chief Scientific & Medical Officer · b. 1953
Mr. Richard Gerald AdcockPresident, CEO & Director · b. 1969
Mr. David C. SachsChief Financial Officer · b. 1978
Ms. Regan J. LauerChief Accounting Officer · b. 1970
Dr. Barry J. Simon M.D.Chief Corporate Affairs Officer & Director · b. 1965
Dr. Enrique Diloné Ph.D., RACChief Technology Officer · b. 1967
Ms. Sarah SingletonChief Communications Officer & Head of Patient Advocacy
Ms. Emily ArisonSenior Vice President of Human Resources
Dr. Leonard S. Sender M.D.Chief Medical Officer of Liquid Tumors & Cell Therapy
Dr. Sandeep K. Reddy M.D.Chief Medical Officer

Financials

Income Statement

Line item	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$113.29M	$14.74M	$622.00K	$240.00K	$934.00K	$605.00K	$43.00K	$47.00K	$45.00K	$44.00K	$236.00K	$641.00K	$600.00K
Cost of Revenue	$753.00K	$17.55M	$18.51M	$24.19M	-	$9.15M	$9.01M	$-3.11M	-	-	-	$323.00K	$253.00K
Gross Profit	$112.53M	$14.74M	$622.00K	$240.00K	$934.00K	$605.00K	$-8.97M	$3.16M	$45.00K	$44.00K	$236.00K	$641.00K	$347.00K
Operating Income	$-256.03M	$-344.18M	$-362.25M	$-351.30M	$-330.28M	$-220.88M	$-66.91M	$-98.39M	$-99.12M	$-124.50M	$-238.88M	$-6.21M	$-2.27M
EBITDA	$-223.56M	$-264.43M	$-478.66M	$-351.88M	$-320.75M	$-204.22M	$-56.85M	$-86.74M	$-90.73M	$-117.71M	$-235.71M	$-5.68M	$-1.58M
Net Income	$-351.40M	$-413.56M	$-583.20M	$-416.57M	$-346.79M	$-221.85M	$-65.79M	$-96.23M	$-96.42M	$-120.81M	$-236.88M	$-6.21M	$-2.05M
R&D	$207.88M	$190.14M	$232.37M	$248.15M	$195.96M	$139.51M	$48.88M	$53.42M	$39.78M	$26.55M	$11.43M	$1.59M	$446.00K
Interest Expense	$112.53M	$131.66M	$86.72M	$47.15M	$14.85M	$9.07M	$5.92M	$433.00K	$618.00K	$66.00K	$0	$0	$463.00K

Balance Sheet

Line item	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$501.90M	$382.93M	$504.45M	$362.36M	$468.91M	$221.38M	$143.12M	$181.95M	$250.44M	$317.50M	$366.85M	$60.83M	$2.10M
Total Liabilities	$1.00B	$871.06M	$1.09B	$812.18M	$712.82M	$339.87M	$22.44M	$35.94M	$31.60M	$24.08M	$10.85M	$2.40M	$5.00M
Total Equity	$-499.57M	$-489.10M	$-586.99M	$-447.33M	$-242.17M	$-119.81M	$120.68M	$146.01M	$218.84M	$293.42M	$356.00M	$58.42M	$-2.90M
Cash	$88.33M	$143.43M	$265.45M	$104.64M	$181.10M	$34.91M	$15.51M	$16.82M	$23.87M	$8.08M	$175.91M	$59.10M	$350.00K
Total Debt	$878.12M	$504.17M	$726.72M	$723.77M	$645.66M	$275.55M	$14.85M	$6.91M	$7.27M	$8.21M	$2.47M	$265.00K	$1.76M
Net Debt	$789.78M	$360.74M	$461.27M	$619.13M	$464.56M	$240.63M	$-660.00K	$-9.91M	$-16.60M	$127.00K	$-173.44M	$-58.84M	$1.41M

Cash Flow

Line item	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Operating Cash Flow	$-304.94M	$-391.24M	$-366.76M	$-337.51M	$-274.42M	$-171.72M	$-152.11M	$-63.38M	$-48.78M	$-38.59M	$-25.30M	$-5.35M	$-668.00K
Investing Cash Flow	$-149.80M	$-12.25M	$-30.47M	$27.30M	$-84.89M	$-19.81M	$18.55M	$57.10M	$99.55M	$-113.67M	$-175.22M	$-299.00K	$-3.00K
Financing Cash Flow	$400.24M	$281.63M	$558.34M	$233.61M	$505.44M	$150.68M	$114.28M	$-771.00K	$-34.98M	$-15.56M	$317.33M	$64.41M	$905.00K
Capital Expenditure	$3.85M	$6.89M	$30.58M	$78.16M	$33.56M	$1.67M	$4.29M	$13.10M	$34.81M	$6.56M	$2.24M	$299.00K	$3.00K
Free Cash Flow	$-308.78M	$-398.12M	$-397.34M	$-415.67M	$-307.98M	$-173.39M	$-156.40M	$-76.48M	$-83.59M	$-45.15M	$-27.55M	$-5.65M	$-671.00K
Dividends Paid	-	-	-	$616.00K	$334.44M	$4.44M	$2.28M	-	-	-	-	-	-

Earnings

Report Date	Nov 3, 2026	Aug 4, 2026	May 7, 2026	Mar 3, 2026	Nov 4, 2025	Aug 5, 2025	May 7, 2025	Mar 3, 2025	Nov 12, 2024	Aug 12, 2024	May 9, 2024	Mar 19, 2024	Nov 9, 2023	Aug 8, 2023	May 11, 2023	Mar 1, 2023	Nov 9, 2022	Aug 8, 2022	May 10, 2022	Mar 1, 2022	Nov 12, 2021	Aug 12, 2021	May 14, 2021	Mar 4, 2021	Nov 9, 2020	Aug 7, 2020	May 11, 2020	Mar 25, 2020	Nov 5, 2019	Aug 6, 2019	May 8, 2019	Mar 13, 2019	Nov 7, 2018	Aug 6, 2018	May 7, 2018	Mar 12, 2018	Nov 7, 2017	Aug 7, 2017	May 8, 2017	Mar 15, 2017	Nov 10, 2016	Aug 15, 2016	May 16, 2016	Mar 30, 2016	Nov 12, 2015	Sep 10, 2015
EPS Estimate	$-0.08	$-0.09	$-0.07	$-0.11	$-0.10	$-0.10	$-0.16	$-0.13	$-0.18	$-0.15	$-0.16	$-0.18	$-0.18	$-0.23	$-0.27	$-0.22	$-0.21	$-0.24	$-0.22	$-0.21	$-0.20	$-0.12	$-0.41	$-0.18	$-0.18	$-0.19	$-0.17	$-0.20	$-0.18	$-0.24	$-0.23	$-0.31	$-0.37	$-0.38	$-0.34	$-0.33	$-0.32	$-0.31	$-0.36	$-0.43	$-0.45	$-0.58	$-0.37	$-0.23	$-0.10	$-0.13
EPS Actual	-	$-0.08	$-0.08	$-0.06	$-0.07	$-0.10	$-0.15	$-0.08	$-0.12	$-0.20	$-0.20	$-0.38	$-0.19	$-0.32	$-0.27	$-0.27	$-0.28	$-0.24	$-0.26	$-0.23	$-0.22	$-0.23	$-0.21	$-0.30	$-0.20	$-0.20	$-0.19	$-0.16	$-0.16	$-0.17	$-0.22	$-0.22	$-0.30	$-0.35	$-0.35	$-0.31	$-0.30	$-0.29	$-0.30	$-0.29	$-0.39	$-0.41	$-0.38	$-0.97	$-0.55	$-1.29
Surprise	-	11.11%	-14.29%	45.75%	30.00%	0.00%	6.25%	38.46%	33.33%	-33.33%	-25.00%	-111.11%	-5.56%	-39.13%	0.00%	-22.73%	-33.33%	0.00%	-18.18%	-9.52%	-10.00%	-91.67%	48.78%	-66.67%	-11.11%	-5.26%	-11.76%	20.00%	11.11%	29.17%	4.35%	29.03%	18.92%	7.89%	-2.94%	6.06%	6.25%	6.45%	16.67%	32.56%	13.33%	29.31%	-2.70%	-321.74%	-450.00%	-892.31%
Timing	Pre-market	Pre-market	Pre-market	-	After-hours	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	After-hours	After-hours	Pre-market	After-hours	Pre-market	After-hours	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours

Key Statistics & Ratios

Market Cap: $9.16B
Enterprise Value: $9.60B
Trailing P/E: 0.00
Forward P/E: 123.46
Price / Sales: 55.23
Price / Book: 0.00
EPS: $-0.95
Book Value: $-0.994
Revenue (TTM): $165.79M
Gross Profit (TTM): $164.70M
EBITDA: $-235.30M
Profit Margin: 0.00%
Operating Margin: -120.41%
Return on Equity: 0.00%
Return on Assets: -30.54%
Shares Outstanding: 1.06B
Shares Float: 406.64M
Beta: 0.14
Dividend Yield: 0.00%
Dividend Rate: $0
Payout Ratio: 0.00%

Analyst Ratings

Strong Sell

Based on 5 analystsTarget $12.75

Strong Buy
3
Buy
2

Ownership Breakdown

Institutions: 19.80%
Insiders: 62.17%
Retail / Other: 18.03%

Top Institutional Holders

BlackRock Inc
26.35M2.49%
State Street Corp
17.71M1.67%
Vanguard Portfolio Management, LLC
16.32M1.54%
Vanguard Capital Management, LLC
15.13M1.43%
D. E. Shaw & Co LP
11.55M1.09%
Two Sigma Investments LLC
11.10M1.05%
Geode Capital Management, LLC
8.03M0.76%
Millennium Management LLC
5.58M0.53%
Morgan Stanley - Brokerage Accounts
4.02M0.38%
HRT FINANCIAL LLC
3.93M0.37%
Woodline Partners LP
3.45M0.33%
The Goldman Sachs Group Inc
3.24M0.31%
UBS Group AG
2.94M0.28%

Top Fund Holders

State Street® SPDR® S&P® Biotech ETF
13.15M1.24%
Vanguard MStar Total Stk Mkt Idx Invest
11.62M1.10%
iShares Russell 2000 ETF
9.81M0.93%
Vanguard Small Cap Index
8.43M0.80%
Vanguard MStar Small Cap Growth Indx Inv
4.83M0.46%
Fidelity Small Cap Index
4.19M0.40%
iShares Russell 2000 Growth ETF
3.62M0.34%